The European Medicines Agency Accepts Marketing Authorisation Application for Intrarosa for the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women

Endoceutics Inc., a private Quebec City based biopharma company, today announced that the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product IntrarosaTM, intended for the treatment of vulvar and vaginal atrophy in postmenopausal women. IntrarosaTM will be available as a 6.5 mg pessary. The active substance of [PR.com]

Pharmaceutical Stocks

[stock-ticker]

© 2017 Drugs News All rights reserved.       Privacy Policy       Contact Us